ICER’s Value Assessments Inform Pricing Decisions

Although new technologies have brought about novel therapies for previously unaddressed diseases, setting prices for these sometimes life-saving treatments remains challenging. One route involves relying on value assessments put forth by the Institute for Clinical and Economic Review (ICER).

“Cell and gene therapies hold tremendous promise at tremendous prices, which leads to the question: How much is a cure worth if it’s unaffordable?” Read more here.

(Source: Alisha Green, San Francisco Business Times, 10/1/21)